Table of Contents
ISRN Oncology
Volume 2014, Article ID 793695, 6 pages
http://dx.doi.org/10.1155/2014/793695
Research Article

The Human Epidermal Growth Factor Receptor 2 Screening Tests for Breast Cancer Suggested by the New Updated Recommendation of the American Society of Clinical Oncology/College of American Pathologists Will Involve a Rise of the In-Situ Hybridization Tests for the European Laboratories of Pathology

Biopathology and Oncology Departments, Institut Jean Godinot, Unicancer, 1 rue du Général Koenig CS80014, 51726 Reims Cedex, France

Received 13 February 2014; Accepted 20 March 2014; Published 22 April 2014

Academic Editors: G. Gatti, G. E. Kim, and T. Yokoe

Copyright © 2014 Christian Garbar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent et al., “Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012,” European Journal of Cancer, vol. 49, no. 6, pp. 1374–1403, 2013. View at Google Scholar
  2. A. Goldhirsch, E. Winer, A. Coates et al., “Personalizing the treatment of women with early breast cancer: highlights of the St Gallen Internalional Expert Consensus on the primary therapy of early breast cancer,” Annals of Oncology, vol. 24, no. 9, pp. 2206–2223, 2013. View at Publisher · View at Google Scholar
  3. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi, “The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine,” The Oncologist, vol. 14, no. 4, pp. 320–368, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. A. C. Wolff, M. E. H. Hammond, J. N. Schwartz et al., “American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer,” Journal of Clinical Oncology, vol. 25, no. 1, pp. 118–145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Wolff, E. Hammond, D. Hicks et al., “Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update,” Journal of Clinical Oncology, vol. 31, pp. 3997–4013, 2013. View at Google Scholar
  7. A. M. Gown, L. C. Goldstein, T. S. Barry et al., “High concordance between immunohistochemistry and fluorescence In situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system,” Modern Pathology, vol. 21, no. 10, pp. 1271–1277, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. T. A. Thomson, M. M. Hayes, J. J. Spinelli et al., “HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent In situ hybridization,” Modern Pathology, vol. 14, no. 11, pp. 1079–1089, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Rydn, M. Haglund, P.-O. Bendahl et al., “Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer A national survey performed at pathology departments in Sweden,” Acta Oncologica, vol. 48, no. 6, pp. 860–866, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Ross, “Saving lives with accurate HER2 testing,” American Journal of Clinical Pathology, vol. 134, pp. 183–184, 2010. View at Google Scholar
  11. E. Perez, M. Press, A. Dueck et al., “Immunohistochemistry and fluorescence In situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, BCIRG 005),” Breast Cancer Research and Treatment, vol. 138, pp. 99–108, 2013. View at Google Scholar
  12. N. Dendukuri, K. Khetani, M. McIsaac, and J. Brophy, “Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis,” Canadian Medical Association Journal, vol. 176, no. 10, pp. 1429–1434, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Choritz, G. Büsche, and H. Kreipe, “Quality assessment of HER2 testing by monitoring of positivity rates,” Virchows Archiv, vol. 459, no. 3, pp. 283–289, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Penault-Llorca, A. Vincent-Salomon, J.-P. Bellocq et al., “Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France,” Annales de Pathologie, vol. 30, no. 5, pp. 357–373, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. C. Wolff, M. E. H. Hammond, J. N. Schwartz et al., “American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer,” Archives of Pathology and Laboratory Medicine, vol. 131, no. 1, pp. 18–43, 2007. View at Google Scholar · View at Scopus
  16. M. Vergara-Lluri, N. Moatamed, E. Hong, and S. Apple, “High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence In situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines,” Modern Pathology, vol. 25, pp. 1326–1332, 2012. View at Google Scholar
  17. J. S. Ross, “Fluorescence In situ hybridization is the preferred approach over immunohistochemistry for determining HER2 status,” Clinical Chemistry, vol. 57, no. 7, pp. 980–982, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Sauter, J. Lee, J. Bartlett, D. Slamon, and M. Press, “Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1323–1333, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. E. E. Grimm, R. A. Schmidt, P. E. Swanson, S. M. Dintzis, and K. H. Allison, “Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases,” American Journal of Clinical Pathology, vol. 134, no. 2, pp. 284–292, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Hanna, P. Barnes, R. Berendt et al., “Testing for Her2 in breast cancer: current pathology challenges faced in Canada,” Current Oncology, vol. 19, pp. 315–323, 2012. View at Google Scholar
  21. C. Franchet, T. Filleron, A. Cayre et al., “Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study,” Histopathology, vol. 64, no. 2, pp. 274–283, 2013. View at Publisher · View at Google Scholar
  22. A. Mohamed, K. Krajewski, B. Cakar, and C. X. Ma, “Targeted therapy for breast cancer,” The American Journal of Pathology, vol. 183, no. 4, pp. 1096–1112, 2013. View at Google Scholar